articleThe Lancet OncologyJul 9, 2010Closed access

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis

KU Leuven · SIB Swiss Institute of Bioinformatics · +20 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

No abstract available for this paper.

Citation impact

2,136
total citations
FWCI
69.27
Percentile
100%
References
34
Citations per year

Authors

37

Topics & keywords

Keywords
  • KRAS
  • Cetuximab
  • Neuroblastoma RAS viral oncogene homolog
  • Medicine
  • Colorectal cancer
  • Oncology
  • Chemotherapy
  • Internal medicine
No related works found for this paper.

Funding